Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Sandler

Showing results (21-30 of 90) with videos related to

Pageof 9
Sort By:
Expert Opinion on Biological Therapy|March 25, 2017
Prospects and progress of atezolizumab in non-small cell lung cancerJohan Vansteenkiste, Els Wauters, Keunchil Park, et al.
Pain|August 1, 1995
Efficacy of controlled-release codeine in chronic non-malignant pain: a randomized, placebo-controlled clinical trialWilliam Arkinstall, Alan Sandler, Barry Goughnour, et al.
Lung Cancer (Amsterdam, Netherlands)|February 15, 2002
Etoposide, ifosfamide and cisplatin (VIP) plus concurrent radiation therapy for previously untreated limited small cell lung cancer (SCLC): a Hoosier Oncology Group (HOG) phase II studyNasser Hanna, Rafat Ansari, William Fisher, et al.
Gynecologic Oncology|February 10, 2004
Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) StudyKatherine Y Look, Alan Sandler, John A Blessing, et al.
Lung Cancer (Amsterdam, Netherlands)|October 9, 2002
A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancerSumeet Bhatia, Nasser Hanna, Rafat Ansari, et al.
Lung Cancer (Amsterdam, Netherlands)|August 11, 2012
An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastasesAlan Sandler, Vera Hirsh, Martin Reck, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 16, 2011
An open-label, multicenter, three-stage, phase II study of s-1 in combination with cisplatin as first-line therapy for patients with advanced non-small cell lung cancerAlan Sandler, Charles Graham, Maria Baggstrom, et al.
Cancer Chemotherapy and Pharmacology|March 21, 2003
A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979)Sophie Callies, Dinesh P de Alwis, James G Wright, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2003
Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597Gregory A Masters, Lieven Declerck, Charles Blanke, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 26, 2009
A phase II study of paclitaxel + etoposide + cisplatin + concurrent radiation therapy for previously untreated limited stage small cell lung cancer (E2596): a trial of the Eastern Cooperative Oncology GroupLeora Horn, Patricia Bernardo, Alan Sandler, et al.
Pageof 9

Showing results (21-30 of 90) with videos related to

Sort By:
Pageof 9
Expert Opinion on Biological Therapy|March 25, 2017
Prospects and progress of atezolizumab in non-small cell lung cancerJohan Vansteenkiste, Els Wauters, Keunchil Park, et al.
Pain|August 1, 1995
Efficacy of controlled-release codeine in chronic non-malignant pain: a randomized, placebo-controlled clinical trialWilliam Arkinstall, Alan Sandler, Barry Goughnour, et al.
Lung Cancer (Amsterdam, Netherlands)|February 15, 2002
Etoposide, ifosfamide and cisplatin (VIP) plus concurrent radiation therapy for previously untreated limited small cell lung cancer (SCLC): a Hoosier Oncology Group (HOG) phase II studyNasser Hanna, Rafat Ansari, William Fisher, et al.
Gynecologic Oncology|February 10, 2004
Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) StudyKatherine Y Look, Alan Sandler, John A Blessing, et al.
Lung Cancer (Amsterdam, Netherlands)|October 9, 2002
A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancerSumeet Bhatia, Nasser Hanna, Rafat Ansari, et al.
Lung Cancer (Amsterdam, Netherlands)|August 11, 2012
An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastasesAlan Sandler, Vera Hirsh, Martin Reck, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 16, 2011
An open-label, multicenter, three-stage, phase II study of s-1 in combination with cisplatin as first-line therapy for patients with advanced non-small cell lung cancerAlan Sandler, Charles Graham, Maria Baggstrom, et al.
Cancer Chemotherapy and Pharmacology|March 21, 2003
A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979)Sophie Callies, Dinesh P de Alwis, James G Wright, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2003
Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597Gregory A Masters, Lieven Declerck, Charles Blanke, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 26, 2009
A phase II study of paclitaxel + etoposide + cisplatin + concurrent radiation therapy for previously untreated limited stage small cell lung cancer (E2596): a trial of the Eastern Cooperative Oncology GroupLeora Horn, Patricia Bernardo, Alan Sandler, et al.
Pageof 9